Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808870 | 0.88 | TDP1 (0.53) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL16670500 | 0.85 | CYP2C19 (0.41) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL28759548 | 0.85 | CYP2C19 (0.47) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL11586023 | 0.83 | CYP2D6 (0.53) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL31675157 | 0.83 | CYP2D6 (0.53) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL7278100 | 0.83 | TDP1 (0.49) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL809183 | 0.82 | TDP1 (0.47) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL4814074 | 0.82 | CYP2D6 (0.52) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL1744336 | 0.81 | CYP2C19 (0.47) | CYP2C19CYP1A2CYP2D6TDP1CYP2C9 | |
| SCHEMBL7287681 | 0.80 | TDP1 (0.54) | CYP2C19CYP1A2CYP2D6TDP1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107501241-B | Compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative diseases | 梅制药公司 | 2020-10-13 | — | — | CN | disclosed |
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2019-06-27 | — | — | US | disclosed |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2691384-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | MEI Pharma, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012135160-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-1288203-B1 | Cyclic nitrones and pharmaceutical compositions containing them | AVENTIS PHARMA INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1288203-A1 | Cyclic nitrones and pharmaceutical compositions containing them | Aventis Pharmaceuticals Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6211397-B1 | CHLORINATION OF PHOSPHORANES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-03 | — | — | US | disclosed |
| US-5962469-A | PREVENTION OF OXIDATION TISSUE DAMAGE BY FREE RADICALS | HOECHST MARION ROUSSEL INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0863878-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997010218-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1997-03-20 | — | — | WO | disclosed |
| WO-1993005053-A1 | PROCESS FOR PRODUCING α-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | CYP2C19 4703/4885CYP1A2 4829/4885CYP2D6 3722/4885 |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | CYP2C19 4703/4885CYP1A2 4829/4885CYP2D6 3722/4885 |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP2C19 364/4885CYP1A2 224/4885CYP2D6 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.